LA JOLLA, Calif., July 12, 2010 — Some types of prostate tumors are more aggressive and more likely to metastasize than others. Nearly one-third of these aggressive tumors contain a small nest of especially dangerous cells known as neuroendocrine-type cells. More rarely, some aggressive prostate tumors are made up entirely of neuroendocrine-type cells. The presence of neuroendocrine-type cancer cells is associated with a poor prognosis, but spotting these rare cells can be like finding a needle in a haystack. Now, in a study published in the July 13 issue of Cancer Cell, a team of investigators led by Ze’ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has identified a series of proteins that might make it easier for doctors to better diagnose the more metastatic forms of prostate cancer.
“In identifying this protein pathway, which determines the formation of neuroendocrine tumors, we’ve identified new markers that can be used to distinguish the dangerous cells and find new targets for therapy,” said Dr. Ronai, associate director of Sanford-Burnham’s National Cancer Institute-designated Cancer Center.
This study uncovers a protein named Siah2, which initiates a cascade of molecular events that turns a non-malignant tumor into a metastatic neuroendocrine tumor. In collaboration with four other medical centers across the United States, Dr. Ronai and his colleagues analyzed human prostate cancer samples and found that Siah2 and the other proteins it triggers is detected more often in the aggressive neuroendocrine forms of prostate tumors than in other types. By acting as markers for particularly aggressive prostate cancers, Siah2 and its partners could provide doctors with an early warning sign for tumors that are likely to metastasize.
To further validate these findings, the Siah2 gene was inactivated in mice already prone to developing aggressive prostate tumors. Although benign growths still appeared, they failed to develop into neuroendocrine tumors.
“When we inhibit the Siah2 pathway in mice, we eliminate the neuroendocrine-type cells from the prostate tumors,” explained Jianfei Qi, Ph.D., postdoctoral researcher in Dr. Ronai’s laboratory and first author of the study. “Since prostate cancers containing neuroendocrine-type cells are resistant to current therapies, we are pleased to find that targeting Siah2 might provide an alternate approach to treating this disease.”
Members of the Sanford-Burnham research team are now looking for chemical compounds that inhibit the activity of Siah2 or other proteins along the chain. They hope to find a new drug that will block the series of molecular events leading to the formation of neuroendocrine-type cancer cells, thus keeping prostate tumors in check.
This study was supported by a grant from the National Cancer Institute, a division of the National Institutes of Health (NIH). For more information about Sanford-Burnham research, visit http://beaker.sanfordburnham.org.
Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA. Siah2-dependent concerted activity of HIF & FoxA2 regulates formation of neuroendocrine phenotype & neuroendocrine prostate tumors. Cancer Cell. Published July 13, 2010.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top independent research institutions nationally for NIH grant funding and among the top organizations worldwide for its research impact. From 1999 — 2009, Sanford-Burnham ranked #1 worldwide among all types of organizations in the fields of biology and biochemistry for the impact of its research publications, defined by citations per publication, according to the Institute for Scientific Information. According to government statistics, Sanford-Burnham ranks #2 nationally among all organizations in capital efficiency of generating patents, defined by the number of patents issued per grant dollars awarded.
Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a nonprofit public benefit corporation. For more information, please visit www.sanfordburnham.org.